Evidence map›Paper›PMID 39143618›Full record

ArticleDiagnostic pathology2024

Clinicopathological and genetic characterization of radiotherapy-induced undifferentiated pleomorphic sarcoma following breast cancer: a case series of three tumors and comprehensive literature review.

Ting Lei, Zhiyi Shen, Mengjia Shen, Lingfang Du, Yongqiang Shi, Yan Peng, Zidi Zhou, Wenyue Da, Xi Chen, Qing Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostic pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ting LeiDepartment of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, P.R. China.
Zhiyi ShenDepartment of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, P.R. China.
Mengjia ShenDepartment of Pathology, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, 610041, Sichuan, China.
Lingfang DuClinical Medical Research Center, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, P.R. China.
Yongqiang ShiDepartment of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, P.R. China.
Yan PengDepartment of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, P.R. China.
Zidi ZhouDepartment of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, P.R. China.
Wenyue DaDepartment of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, P.R. China.
Xi ChenDepartment of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, P.R. China.
Qing LiDepartment of Pathology, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, P.R. China. liqblk@163.com.

Funding

Qing Li 2022260Ting Lei QN202114
6 · The paper itself

Abstract

aimsCompared to primary breast sarcoma (BSs), radiotherapy-induced sarcoma (RIS) is a less frequent type of secondary breast sarcoma. Undifferentiated pleomorphic sarcoma (UPS) is an even rarer occurrence within the RIS category. This study aimed to present the clinicopathologic and molecular features of breast radiotherapy-induced UPS.

methodsA retrospective study was conducted at the Third Affiliated Hospital of Soochow University to analyze three patients with radiation-induced undifferentiated pleomorphic sarcoma (UPS) following breast cancer, spanning from 2006 to 2023. The clinical and pathological variables were extracted from the medical records, while immunohistochemistry was employed to analyze the immunophenotypes of these tumors. Genomic characteristics were assessed through DNA and RNA sequencing techniques. Another 15 cases from the literature were also reviewed to better characterize the tumor.

resultsThe affected areas encompass the chest wall and breasts, with an incubation period ranging from 6 to 17 years. The tumor cells exhibit pleomorphism and demonstrate a high degree of pathological mitosis. Notably, two cases displayed an accelerated disease progression, characterized by recurrent tumors and metastases occurring within short intervals of 48 and 7 months respectively subsequent to the initial diagnosis. The two prevailing identified genes were TP53 (2/3, 66.7%) and RB1 (1/3, 33.3%). Through analysis of somatic copy number variation (CNV), it was discovered that two oncogenes, MCL1 (1/3, 33.3%) and MYC (1/3, 33.3%), had experienced gains in CNV. The Tumor Mutational Burden (TMB) values for case 1, case 2, and case 3 were 5.9 mut/Mb, 1.0 mut/Mb, and 3.0 mut/Mb, respectively. Moreover, the analysis of RNA-NGS (next-generation sequencing) revealed the presence of a novel gene fusion, named COL3A1-GULP1, in case 2.

conclusionsBased on our thorough analysis of research findings and previous reports, it is evident that radiotherapy-induced UPS exhibits a highly diverse and frequently severe clinical and biological behavior. Identifying tumor formation using genome sequencing can help understand its biological behavior and determine personalized treatments.

Indexed as

Breast NeoplasmsNeoplasms, Radiation-InducedSarcomaAdultAgedBiomarkers, TumorFemaleHumansMiddle AgedRetinoblastoma Binding ProteinsRetrospective StudiesUbiquitin-Protein LigasesBiomarkers, TumorRB1 protein, humanRetinoblastoma Binding ProteinsUbiquitin-Protein LigasesCOL3A1-GULP1Poor prognosisRadiotherapy-induced sarcoma (RIS)RB1TP53Undifferentiated pleomorphic sarcoma (UPS)

Identifiers

PMID39143618
PMCPMC11325744

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.